contribut
equal
j
u
r
n
l
p
r
e
p
r
f
highlight
review
discoveri
develop
process
broadspectrum
antivir
agent
summar
inform
safeinman
agent
freeli
access
databas
studi
increas
number
broadspectrum
antivir
expand
spectrum
indic
identifi
drug
combin
treatment
emerg
reemerg
viral
infect
viral
diseas
one
lead
caus
morbid
mortal
world
virusspecif
vaccin
antivir
drug
power
tool
combat
viral
diseas
howev
broadspectrum
antivir
agent
bsaa
ie
compound
target
virus
belong
two
viral
famili
could
provid
addit
protect
gener
popul
emerg
reemerg
viral
diseas
reinforc
arsen
avail
antivir
option
review
discoveri
develop
bsaa
summar
inform
safeinman
agent
freeli
access
databas
http
drugvirusinfo
futur
ongo
preclin
clinic
studi
increas
number
bsaa
expand
spectrum
indic
identifi
drug
combin
treatment
emerg
reemerg
viral
infect
well
coinfect
virus
one
major
caus
morbid
mortal
world
dali
collabor
diseas
et
al
howard
fletcher
market
compar
develop
new
virusspecif
drug
vaccin
significantli
reduc
cost
timelin
clinic
avail
pizzorno
et
al
zheng
et
al
detail
step
bsaa
repurpos
discoveri
novel
antivir
activ
cell
cultur
postmarket
studi
moreov
summar
current
avail
inform
bsaa
freeli
avail
databas
focus
antivir
alreadi
test
human
antivir
antibacteri
antiprotozo
anthelmint
etc
final
discuss
futur
perspect
use
safeinman
bsaa
treatment
emerg
reemerg
viral
infect
well
viral
bacteri
coinfect
discoveri
novel
activ
bsaa
start
expos
cell
candid
antivir
agent
differ
concentr
infect
cell
viru
mock
immort
cancer
cell
cultur
cocultur
express
appropri
viral
receptor
commonli
use
first
step
halfmaxim
cytotox
concentr
compound
calcul
base
doserespons
curv
obtain
mockinfect
cell
halfmaxim
effect
concentr
calcul
base
analysi
curv
obtain
infect
cell
statist
analys
help
determin
differ
signific
given
inher
variabl
experi
j
u
r
n
l
p
r
e
p
r
f
meneghini
hamasaki
rel
effect
drug
defin
select
index
si
cell
viabil
assay
cell
death
assay
commonli
use
assess
cytotox
efficaci
bsaa
figur
cell
viabil
assay
includ
mtt
mt
resazurin
similar
assay
mitochondri
membran
potentialdepend
dyesbas
assay
esteras
cleav
dyebas
assay
atpadp
assay
assay
measur
glycolyt
flux
oxygen
consumpt
cell
death
assay
includ
ldh
enzym
leakag
assay
membran
imperm
dyebas
assay
apoptosi
assay
annexin
v
tunel
caspas
assay
shen
et
al
exampl
cell
titer
glo
ctg
assay
quantifi
atp
indic
metabol
activ
live
cell
wherea
cell
tox
green
assay
use
fluoresc
asymmetr
cyanin
dye
stain
dna
dead
cell
bosl
et
al
bulanova
et
al
ianevski
et
al
muller
et
al
viral
strain
cell
line
express
report
protein
also
use
assess
efficaci
bsaa
infect
cell
exampl
tzmbl
cell
express
firefli
luciferas
control
ltr
promot
allow
quantit
bsaa
action
infect
tatprotein
express
integr
proviru
use
firefli
luciferas
assay
sarzottikelso
et
al
xing
et
al
rfpexpress
rvfv
nanolucexpress
chikv
rrv
well
gfpexpress
fluav
hcv
hmpv
also
allow
identif
novel
activ
sever
bsaa
andersen
et
al
bosl
et
al
de
graaf
et
al
habjan
et
al
ianevski
et
al
jupil
et
al
kittel
et
al
lee
et
al
utt
et
j
u
r
n
l
p
r
e
p
r
f
al
addit
qpcrrtqpcr
rnadna
sequenc
rnadna
hybrid
immunoand
plaqu
assay
well
system
could
use
detect
inhibitori
effect
bsaa
boonham
et
al
fischer
et
al
konig
et
al
laamiri
et
al
landri
perez
et
al
sashit
zhou
et
al
interestingli
sirna
shrna
approach
use
identif
bsaa
target
dean
et
al
puschnik
et
al
novel
activ
emetin
discov
recent
use
ctgplaqu
assay
human
nonmalign
rpe
cell
moreov
novel
antivir
activ
drug
identifi
use
rfpexpress
rvfv
gfpexpress
hmpv
fluav
strain
rpe
cell
andersen
et
al
given
emetin
also
inhibit
zikv
ebov
rabv
cmv
infect
chave
valadao
et
al
macgibeni
et
al
mukhopadhyay
et
al
shen
et
al
yang
et
al
fdaapprov
antiprotozo
drug
may
repres
promis
safeinman
bsaa
candid
immort
cell
culturescocultur
report
viral
strain
repres
excel
model
system
discoveri
novel
activ
safeinman
bsaa
howev
genet
modifi
system
certain
limit
attenu
incomplet
viru
replic
cycl
accumul
mutat
repeat
cell
viru
passag
defect
innat
immun
respons
viral
counterj
u
r
n
l
p
r
e
p
r
f
respons
etc
carter
shieh
therebi
novel
antivir
activ
bsaa
valid
primari
human
cell
use
differ
viral
strain
includ
wildtyp
virus
differ
viral
load
differ
time
compound
addit
differ
endpoint
measur
compound
concentr
rang
primari
cell
cultur
give
accur
imag
drug
respons
alv
et
al
denisova
et
al
koban
et
al
postnikova
et
al
low
popul
doubl
level
therefor
close
recapitul
physiolog
condit
observ
vivo
primari
cell
cell
isol
directli
tissu
blood
use
enzymat
mechan
method
cell
character
high
degre
special
often
fulli
differenti
thu
requir
defin
cultur
condit
serumfre
media
order
preserv
origin
phenotyp
peripher
blood
mononuclear
pbmc
placent
amniot
fetal
primari
cultur
well
vaginalcerv
epitheli
male
germ
cell
use
intens
valid
bsaa
activ
barrow
et
al
denisova
et
al
fink
et
al
rausch
et
al
robinson
et
al
establish
human
airway
gut
skin
cerebr
liver
kidney
breast
retina
brain
organoid
allow
research
studi
toxic
efficaci
sever
safeinman
bsaa
coronavirus
influenza
enterovirus
rotavirus
flavivirus
li
et
al
sacramento
et
al
watanab
et
al
xu
et
al
yin
et
al
yin
et
al
yin
et
al
zhou
et
al
howev
ipsc
esc
ipscsescsderiv
organoid
disadvantag
human
primari
cell
genet
differ
linetolin
organoid
batchtobatch
variabl
hand
model
allow
research
predict
behavior
virus
vivo
therefor
reduc
anim
use
case
anim
model
unavail
initi
clinic
trial
exampl
novel
antizikv
activ
enoxacin
amodiaquin
niclosamid
discov
recent
use
human
neural
progenitor
cell
human
pluripot
stem
cellderiv
cortic
neural
progenitor
cell
human
induc
neural
stem
cell
respect
cairn
et
al
xu
et
al
zhou
et
al
enoxacin
oral
broadspectrum
fluoroquinolon
antibiot
also
possess
antihcv
activ
immort
cell
cultur
kashiwas
et
al
young
et
al
amodiaquin
antimalaria
drug
also
possess
antivir
activ
denv
hcv
rrv
sinv
wnv
efv
ebov
lasv
rabv
vzv
immort
cell
cultur
boonyasuppayakorn
et
al
hulseberg
et
al
mazzon
et
al
niclosamid
oral
bioavail
anthelmint
drug
inhibit
broadest
rang
virus
vitro
case
vivo
cairn
et
al
fang
et
al
huang
et
al
hulseberg
et
al
jurgeit
et
al
kao
et
al
mazzon
et
al
stachulski
et
al
wang
et
al
wu
et
al
safeinman
bsaa
repres
promis
drug
candid
vitro
ex
vivo
model
fulli
reflect
complex
physiolog
live
organ
therefor
sever
vivo
model
develop
test
novel
antivir
activ
bsaa
includ
immunocompet
genet
chemic
immunocompromis
mice
guinea
pig
hamster
ferret
pig
macaqu
anim
figur
often
anim
requir
higher
concentr
experiment
antivir
compar
effect
vitro
concentr
moreov
rel
difficult
achiev
micromolar
vivo
exampl
aminoglycosid
antibiot
kasugamycin
neomycin
success
test
zikv
fluav
infect
mice
gopinath
et
al
polyeth
antibiot
salinomycin
also
show
antifluav
effect
mice
jang
et
al
addit
investig
anticanc
agent
flavopiridol
effect
fluav
mice
find
support
develop
bsaa
j
u
r
n
l
p
r
e
p
r
f
clinic
trial
critic
timeconsum
step
drug
candid
journey
approv
figur
howev
safeinman
bsaa
make
journey
rel
short
alreadi
phase
sometim
iia
clinic
trial
antibacteri
antiprotozo
anticanc
etc
agent
ie
administ
subtherapeut
dose
healthi
volunt
ensur
drug
harm
particip
thu
safeinman
bsaa
enter
phase
ii
iii
assess
efficaci
effect
safeti
side
effect
drug
clinic
import
howev
differenti
acut
chronic
viral
infect
repurpos
bsaa
given
drug
concentr
durat
treatment
could
differ
therefor
drug
safeti
issu
consid
develop
databas
safeinman
bsaa
avail
http
drugvirusinfo
figur
drug
annot
obtain
pubchem
drugbank
drugcentr
pubm
clinicaltrialsgov
databas
thu
safeinman
bsaa
may
repres
drug
candid
prophylaxi
treatment
coronaviru
infect
bsaa
could
combin
antivir
agent
obtain
synergist
addit
effect
certain
virus
zheng
et
al
fu
et
al
kuivanen
et
al
contrast
individu
drug
combin
bsaa
could
use
target
even
broader
rang
virus
foucquier
guedj
zheng
et
al
combin
could
serv
front
line
therapeut
poorli
character
emerg
virus
reemerg
drugresist
viral
strain
exampl
cocktail
nitazoxanid
favipiravir
niclosamid
could
develop
treatment
virus
belong
famili
fifti
bsaa
possess
antivir
also
antibacteri
activ
figur
tabl
schor
einav
moreov
agent
approv
antibiot
withdrawn
addit
bsaa
show
activ
wide
rang
medic
import
human
pathogen
includ
fungi
protozoa
parasit
tabl
montoya
krysan
point
pathogen
util
common
mechan
infect
host
moreov
structureact
relationship
analysi
bsaa
suggest
agent
doxycyclin
artesun
omeprazol
nitazoxanid
suramin
azithromycin
minocyclin
chloroquin
could
novel
antibacteri
antiprotozo
antifung
anthelmint
activ
figur
confirm
could
lead
develop
broadspectrum
antiinfect
drug
bsaa
could
also
serv
treatment
comorbid
therefor
simplifi
therapi
lower
cost
tabl
exampl
concomit
action
ezetimib
statin
could
benefici
treatment
hypertens
sever
viral
infect
patient
comorbid
review
process
bsaa
develop
summar
inform
safeinman
agent
freeli
avail
databas
hope
preclin
clinic
studi
bsaa
harmon
data
collect
standard
furthermor
followup
studi
well
result
ongo
final
termin
clinic
trial
made
publicli
avail
allow
priorit
translat
emerg
exist
bsaa
clinic
practic
would
allow
bsaa
play
pivot
role
battl
emerg
reemerg
viral
diseas
antivir
activ
either
studi
report
